In today’s rapidly evolving biopharma landscape, traditional sales forecasting models are no longer sufficient. The once straightforward approach—relying heavily on historical sales data and standard reimbursement assumptions—has been upended by a comp…

In an era where innovation and market expansion are the lifeblood of pharmaceutical success, the ability to identify and capitalize on cross-border licensing opportunities has never been more critical. Yet, navigating the complex web of global patent l…

In the rapidly evolving landscape of global pharmaceuticals, understanding the nuanced differences between the U.S. and European patent systems isn’t just academic—it’s a strategic imperative. A recent analysis by Drug Patent Watch sheds light on six c…

In the high-stakes world of pharmaceutical investing, the clock is always ticking. Patent expirations loom large, threatening to erode billions in revenue overnight and leaving investors and companies alike scrambling for strategic insights. But what i…

In the relentless quest to curb soaring prescription drug costs, one often-overlooked mechanism is gaining renewed attention: march-in rights. As the debate over drug affordability intensifies, understanding this tool could be pivotal in shaping future…

In the rapidly evolving landscape of pharmaceuticals, the traditional approach to generic drug portfolios is facing a critical inflection point. The once straightforward strategy of expanding generics to maximize market share is now riddled with comple…